Xlife Sciences AG (SWX: XLS)
Switzerland
· Delayed Price · Currency is CHF 25.00
-0.40 (-1.57%)
Jan 3, 2025, 9:00 AM CET
Xlife Sciences AG Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 0.99 | 0.99 | 1.03 | 0.81 | 0.4 | 0.51 |
| Revenue Growth (YoY) | -1.32% | -3.85% | 27.53% | 103.14% | -22.92% | - |
| Cost of Revenue | 0.45 | 0.54 | 0.84 | 0.45 | 0.42 | 0.34 |
| Gross Profit | 0.54 | 0.45 | 0.19 | 0.36 | -0.03 | 0.18 |
| Selling, General & Admin | 3.12 | 4.75 | 5.2 | 5.53 | 2.96 | 0.89 |
| Other Operating Expenses | 0.05 | -0.02 | -0.05 | -0 | 0.04 | 0.03 |
| Operating Expenses | 19.2 | 20.75 | 21.17 | 5.59 | 3.07 | 0.95 |
| Operating Income | -18.66 | -20.31 | -20.98 | -5.23 | -3.09 | -0.77 |
| Interest Expense | -0.31 | -0.39 | -0.69 | -0.5 | -0.18 | -0.57 |
| Interest & Investment Income | 0 | 0.03 | 0.21 | 0.1 | 0 | 0 |
| Earnings From Equity Investments | -8.01 | -7.8 | -9.02 | -0.97 | 0.17 | 0.03 |
| Currency Exchange Gain (Loss) | -0.74 | -0.74 | -0.24 | -0.13 | -0.01 | 1.12 |
| Other Non Operating Income (Expenses) | - | - | -0 | 0 | 0 | - |
| EBT Excluding Unusual Items | -27.72 | -29.21 | -30.72 | -6.73 | -3.12 | -0.19 |
| Gain (Loss) on Sale of Investments | 20.78 | 15.88 | 34.76 | -18.12 | 24.31 | 1.22 |
| Asset Writedown | -0 | -0 | -0 | - | - | - |
| Other Unusual Items | 17.87 | 17.87 | - | 78.05 | - | - |
| Pretax Income | 10.92 | 4.53 | 4.04 | 53.19 | 21.2 | 1.03 |
| Income Tax Expense | -4.72 | -4.74 | -4.74 | -0.08 | 0.09 | - |
| Earnings From Continuing Operations | 15.64 | 9.27 | 8.78 | 53.28 | 21.1 | 1.03 |
| Minority Interest in Earnings | 5.59 | 5.61 | 5.53 | 0.14 | 0.36 | 0.02 |
| Net Income | 21.24 | 14.88 | 14.31 | 53.42 | 21.46 | 1.05 |
| Net Income to Common | 21.24 | 14.88 | 14.31 | 53.42 | 21.46 | 1.05 |
| Net Income Growth | 31.65% | 3.96% | -73.21% | 148.91% | 1943.57% | - |
| Shares Outstanding (Basic) | 6 | 5 | 5 | 5 | 4 | 3 |
| Shares Outstanding (Diluted) | 8 | 7 | 7 | 6 | 6 | 4 |
| Shares Change (YoY) | 12.33% | -0.17% | 17.26% | 4.77% | 60.85% | - |
| EPS (Basic) | 3.76 | 2.73 | 2.72 | 11.30 | 5.62 | 0.30 |
| EPS (Diluted) | 2.61 | 2.08 | 2.00 | 8.66 | 3.66 | 0.29 |
| EPS Growth | 17.42% | 4.15% | -76.95% | 136.46% | 1184.65% | - |
| Free Cash Flow | 1.9 | 0.16 | -4.62 | -4.48 | -0.43 | -0.42 |
| Free Cash Flow Per Share | 0.23 | 0.02 | -0.64 | -0.72 | -0.07 | -0.12 |
| Gross Margin | 54.46% | 45.43% | 18.06% | 44.55% | -6.45% | 34.77% |
| Operating Margin | -1884.63% | -2054.30% | -2041.02% | -649.21% | -779.56% | -149.14% |
| Profit Margin | 2144.50% | 1505.34% | 1392.26% | 6627.06% | 5408.47% | 203.99% |
| Free Cash Flow Margin | 191.82% | 15.97% | -449.70% | -555.74% | -108.75% | -82.20% |
| EBITDA | -2.74 | -4.38 | -5.07 | -5.2 | -3.09 | -0.77 |
| EBITDA Margin | -277.04% | - | - | - | - | -148.63% |
| D&A For EBITDA | 15.92 | 15.92 | 15.91 | 0.03 | 0.01 | 0 |
| EBIT | -18.66 | -20.31 | -20.98 | -5.23 | -3.09 | -0.77 |
| EBIT Margin | - | - | - | - | - | -149.14% |
| Effective Tax Rate | - | - | - | - | 0.45% | - |
Source: S&P Capital IQ. Standard template. Financial Sources.